These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29063359)

  • 21. Effect of heparin on chronically induced intravascular coagulation in dogs.
    Owen CA; Bowie EJ
    Am J Physiol; 1975 Aug; 229(2):449-54. PubMed ID: 1163671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis.
    Raffa S; Reverter JC; Seijo S; Tassies D; Abraldes JG; Bosch J; García-Pagán JC
    Clin Gastroenterol Hepatol; 2012 Jan; 10(1):72-8. PubMed ID: 21946303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state.
    Bayazit AK; Kilinç Y
    Pediatr Int; 2001 Dec; 43(6):592-6. PubMed ID: 11737735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism.
    Bulato C; Radu CM; Campello E; Gavasso S; Spiezia L; Tormene D; Simioni P
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):1022-9. PubMed ID: 27013614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inherited hypercoagulable states.
    Rao AK; Sheth S; Kaplan R
    Vasc Med; 1997 Nov; 2(4):313-20. PubMed ID: 9575605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Dysprothrombinemias due to Arg596 Mutations: A Conundrum With No Bleeding Tendency and Venous Thrombosis due to Antithrombin Resistance.
    Girolami A; Ferrari S; Cosi E; Randi ML
    Clin Appl Thromb Hemost; 2019; 25():1076029619841701. PubMed ID: 30968704
    [No Abstract]   [Full Text] [Related]  

  • 30. Heritable coagulopathies in pregnancy.
    Lockwood CJ
    Obstet Gynecol Surv; 1999 Dec; 54(12):754-65. PubMed ID: 10596396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mutation and unusual expression of clotting system-related genes and hypercoagulability].
    Zhao YH; Liu BW
    Sheng Li Ke Xue Jin Zhan; 2003 Oct; 34(4):324-8. PubMed ID: 14992014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 34. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Overview of Thrombophilia and Associated Laboratory Testing.
    Montagnana M; Lippi G; Danese E
    Methods Mol Biol; 2017; 1646():113-135. PubMed ID: 28804823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Haemocoagulative modifications correlated with pregnancy].
    Borrelli AL; De Lucia D; Bernacchi M; Napolitano M; Di Domenico A; Felicetti M; Ferrara C; Meo D; Raffio R; Rivetti A; Sessa M; Tagliaferri A; Torella M
    Minerva Ginecol; 2006 Aug; 58(4):315-22. PubMed ID: 16957675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.
    Leitner JM; Firbas C; Mayr FB; Reiter RA; Steinlechner B; Jilma B
    Clin Pharmacol Ther; 2006 Jan; 79(1):23-34. PubMed ID: 16413239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited.
    Legnani C; Preda L; Palareti G; Lunghi B; Rossi E; Coccheri S
    Haematologica; 2002 Feb; 87(2):182-8. PubMed ID: 11836169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.